LNP-3794
- Generic Name
- LNP-3794
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Phase 1
Completed
- Conditions
- NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT05187858
- Locations
- π§πͺ
Cliniques universitaires Saint-Luc, Brussels, Belgium
π³π±Amsterdam UMC, Amsterdam, Netherlands
π¬π§Sarah Cannon Research Institute, London, United Kingdom
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT04835714
- Locations
- π―π΅
National Cancer Center Hospital East, Chiba, Kashiwa, Japan
π―π΅National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
π―π΅Aichi Cancer Center Hospital, Aichi, Nagoya, Japan
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT04742556
- Locations
- π―π΅
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
π―π΅Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Japan
π―π΅National Cancer Center Hospital East, Chiba, Kashiwa, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath